Literature DB >> 9580594

S-(+)-3-isobutylgaba and its stereoisomer reduces the amount of inflammation and hyperalgesia in an acute arthritis model in the rat.

A K Houghton1, Y Lu, K N Westlund.   

Abstract

The present study investigated whether spinal administration of S-(+)-3-isobutylgaba (S-(+)-3-IBG) or its stereoisomer, R-(-)-3-isobutylgaba (R-(-)-3-IBG), are effective in reducing the hyperalgesia and swelling observed after injection of kaolin and carrageenan into the knee joint of the rat. The effects of pretreatment and post-treatment of S-(+)-3-IBG, R-(-)-3-IBG and artificial cerebrospinal fluid (aCSF) on the swelling, pain-related behavior scores and the heat hyperalgesia induced by knee joint inflammation were compared. Infusion of either S-(+)-3-IBG or R-(-)-3-IBG through a microdialysis fiber, implanted in the dorsal horn of the spinal cord, for 1.5 h before injection of kaolin and carrageenan resulted in a 20 to 30% reduction in joint swelling compared with aCSF-treated controls, and prevented the development of heat hyperalgesia and spontaneous pain. In contrast, infusion of either stereoisomer after the development of inflammation reduced the hyperalgesia but did not reduce the amount of joint swelling compared with aCSF-treated animals. In summary, S-(+)-3-IBG and R-(-)-3-IBG are effective antihyperalgesic agents when administered both before and after joint inflammation. In addition, if administered before injection of kaolin and carrageenan into the knee joint this drug can attenuate joint inflammation. Both the antihyperalgesic and anti-inflammatory properties of this drug probably are mediated through a central neurogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580594

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Management of chronic pain in the rheumatic diseases with insights for the clinician.

Authors:  Mary-Ann Fitzcharles; Yoram Shir
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-08       Impact factor: 5.346

2.  Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.

Authors:  L A Houghton; C Fell; P J Whorwell; I Jones; D P Sudworth; J D Gale
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

Review 3.  Preclinical Assessment of Inflammatory Pain.

Authors:  Milind M Muley; Eugene Krustev; Jason J McDougall
Journal:  CNS Neurosci Ther       Date:  2015-12-10       Impact factor: 5.243

4.  Pregabalin in acute and chronic pain.

Authors:  Dalim Kumar Baidya; Anil Agarwal; Puneet Khanna; Mahesh Kumar Arora
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-07

5.  A comparative study of pre-operative oral clonidine and pregabalin on post-operative analgesia after spinal anesthesia.

Authors:  Anu Prasad; Susmita Bhattacharyya; Atanu Biswas; Mrityunjaya Saha; Sudeshna Mondal; Dona Saha
Journal:  Anesth Essays Res       Date:  2014 Jan-Apr

6.  A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats.

Authors:  David McClelland; Rhian M Evans; Louise Barkworth; Duncan J Martin; Roderick H Scott
Journal:  BMC Pharmacol       Date:  2004-08-04

7.  Silicon-containing GABA derivatives, silagaba compounds, as orally effective agents for treating neuropathic pain without central-nervous-system-related side effects.

Authors:  Hiroshi Fukasawa; Hideaki Muratake; Ai Ito; Hideyuki Suzuki; Yohei Amano; Marina Nagae; Kiyoshi Sugiyama; Koichi Shudo
Journal:  ACS Chem Neurosci       Date:  2014-04-30       Impact factor: 4.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.